Intracranial Electroencephalographic Monitoring: From Subdural to Depth Electrodes

Holger Joswig, David A. Steven, Andrew G. Parrent, Keith W. MacDougall, Seyed M. Mirsattari, Richard S. McLachlan, David C. Diosy, Jorge G. Burneo

ABSTRACT: At the London Health Sciences Centre Epilepsy Program, stereotactically implanted depth electrodes have largely replaced subdural electrodes in the presurgical investigation of patients with drug-resistant epilepsy over the past 4 years. The rationale for this paradigm shift was more experience with, and improved surgical techniques for, stereoelectroencephalography, a possible lower-risk profile for depth electrodes, better patient tolerability, shorter operative time, as well as increased recognition of potential surgical targets that are not accessible to subdural electrodes.

Keywords: Depth Electrodes, Epilepsy Surgery, Stereoelectroencephalography, Subdural Electrodes


As one of Canada’s high-volume adult epilepsy surgery centers, a large number of our patients at London Health Sciences Centre with drug-resistant epilepsy are subjected to intracranial electroencephalographic monitoring. The first subdural electrodes (SE) were implanted in London in 1979 by John Girvin, who had trained at the Montreal Neurological Institute, and soon became our routinely employed invasive diagnostic standard for EEG monitoring. Two techniques is dependent on the question of the electroencephalographic investigation and is a matter of institutional preference.

Although “open” combined SE and DE variants via a craniotomy were not uncommon, our first “stand-alone” stereotactic DE implantation for SEEG at our institution did not take place until 2003 (Figure 1); however, this case was challenged by the lack of technical refinements such as anchor bolts, for example, and SEEG was not resumed until a decade later. In 2013 and 2014, SEEG was performed for 28% of all our invasive electroencephalographic monitoring cases, and this percentage increased to 95% in the past 2 years (Figure 1). The considerations presented in this manuscript factored into our adopted change in practice. Our observation of (clinically silent) magnetic resonance imaging in the 1980s and double-dose gadolinium magnetic resonance imaging in the 1990s.

A paradigm shift toward SEEG has taken place at our institution since 2013, and DE have almost entirely replaced SE (Figure 1). Given the lack of high-quality studies that directly compare the superiority of one technique over the other, the use of SE versus SEEG remains a pivotal discussion and must be viewed as equipoise; the choice between the two techniques is dependent on the question of the electroencephalographic investigation and is a matter of institutional preference.

From the Epilepsy Program, Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada (HJ, DAS, AGP, KWM, SMM, RSM, DCD, JGB).

Received August 21, 2017. Final revisions submitted November 9, 2017.

Correspondence to: Jorge G. Burneo, Epilepsy Program, Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Email: jburneo2@uwo.ca

Downloaded from https://www.cambridge.org/core. IP address: 35.160.27.221, on 30 Apr 2022 at 15:26:42, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/cjn.2018.4
imaging abnormalities after SE placement and expert opinions on lower complication rates prompted a new generation of epileptologists and epilepsy surgeons to give a new impetus to implementing SEEG. In the same vein, increased experience with stereotactic treatments for epilepsy built up our confidence, allowing us to finally overcome the learning curve of Leksell frame-based stereotactic DE implantation as it is now at our institution. It is our anecdotal experience that patients with DE suffer from fewer postoperative headaches and less discomfort than after SE implantation. Cerebrospinal fluid leakage is almost never encountered after SEEG. Last, mean operative time for SEEG is shorter by half an hour ($p < 0.05$; unpublished data).

Over the years, we have learnt to adapt to the "three-dimensional thinking" in SEEG and to appreciate the possibility of investigating deeper structures, such as the insula or deeply situated heterotopic gray matter. In fact, as previously stated, by virtue of their longitudinal recording area, cover both deep and superficial cortical structures, "DE" is a misnomer. Our previous anatomical thinking as subdural implanters developed into a more network-based understanding of epilepsy that emphasizes semiology for planning "punctuate" DE for SEEG and to appreciate the possibility of investigating deeper structures, such as the insula or deeply situated heterotopic gray matter. In fact, as previously stated, as DE, by virtue of their longitudinal recording area, cover both deep and superficial cortical structures, "DE" is a misnomer. Our previous anatomical thinking as subdural implanters developed into a more network-based understanding of epilepsy that emphasizes semiology for planning "punctuate" DE for SEEG, which, in fact, samples less brain. On the basis of these principles and with more experience with DE extraoperative cortical stimulation, we no longer regard SE "more useful than DE to identify areas of eloquent cortex". Yet, we still make use—and will make future use—of SE and grids in selected cases where high-resolution extraoperative cortical stimulation is warranted, as well as in very young patients or in those with contraindications to undergo magnetic resonance imaging for presurgical planning. Specific indications, strengths, and limitations of both techniques, as well as a flow-chart protocol are well summarized in a recent consensus-based expert recommendation.

With the advent of new imaging technologies, the presurgical invasive diagnostic armamentarium continues to grow. A need for a considerate selection of old and new invasive intracranial monitoring techniques or a combination of both to accurately localize the seizure focus remains.

DISCLOSURES

HJ reports personal fees from UCB Canada, non-financial support from Fujirebio Europe N.V. (Ghent, Belgium), outside the submitted work; DAS, KWM, RSM, and DCD have nothing to disclose; AGP reports personal fees from Medtronic, outside the submitted work; SMS reports personal fees from UCB Pharma, personal fees from Eisai Limited, and personal fees from Sunovion Pharmaceuticals Canada, Inc., outside the submitted work; JGB reports grants and personal fees from UCB Pharma, personal fees from Eisai Limited, grants from Epilepsy Canada, and grants from Ontario Brain Institute, outside the submitted work.

STATEMENT OF AUTHORSHIP

HJ: study conceptualization, data collection, manuscript drafting/finalization, literature research, and creation/edit of Figure 1. DAS, AGP, KWM, SMM, RSM, and DCD: data collection and manuscript review. JGB: study conceptualization and supervision, data collection, creation/edit of Figure 1, and manuscript review.

REFERENCES


